Abstract
To investigate the association between the change of IGF-2 level in serum after transcatheter arterial chemoembolization (TACE) and hepatocellular carcinoma (HCC) progression, especially in relation to metastasis. IGF-2 in serum was measured by quantitative sandwich enzyme-linked immunosorbent assay before, 3 days and 4 weeks after TACE in 60 patients with HCC. The occurrence of HCC metastasis was also evaluated, 3 months after TACE. (1) The average serum level of IGF-2 in the 60 patients with HCC was 136.5 ± 87.3 pg/ml; (2) A tendency for increase was observed with heterogenous uptake of octreotide and portal vein thrombosis. Metastatic foci were found in 37/38 patients in the group with IGF-2 increasing (97.0%), in contrast to 3/22 (13.6%) patients with IGF-2 decrease. The increase of IGF-2 level in serum appears to be associated with the occurrence of metastatic HCC after TACE and chemotherapy.
Highlights
In recent years, the incidence of primary liver cancer shows a rising trend, and about one million people die from liver cancer in an average year in the world
The hepatocellular carcinoma (HCC) patients serum Insulin-like growth factor-2 (IGF-2) expression baseline. 30 cases of HCC patients were randomly selected in the preoperative treatment of transcatheter arterial chemoembolization (TACE) combined with octreotide and 30 cases of non-tumor healthy volunteers were considered as control
Serum IGF-2 expression was measured by enzyme-linked immunosorbent sandwich assay (ELISA)
Summary
The incidence of primary liver cancer shows a rising trend, and about one million people die from liver cancer in an average year in the world. As a rich blood supply of solid tumors, HCC grows fast and is easy to form new blood vessels, establish collateral circulation, recurrence and distant metastasis. As a result, it is the largest difficulty in the treatment. Insulin-like growth factor-2 (IGF-2) is an important angiogenic factor during the process which HCC induced neovascularization (El Tayebi et al, 2011; Rehem et al, 2011; Wachter et al, 2012). It can strongly induce angiogenesis and stimulate recurrence and metastasis of HCC. At present we have not yet found the study of IGF-2 expression in serum and prognostic impact which brought by the treatment of octreotide peptide combined with TACE to liver cancer
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
